Myriad Genetics announces retirement of CFO James Evans Myriad Genetics announced that James Evans, CFO of Myriad, has notified the company of his intent to retire in order to attend to family health issues. To ensure a smooth transition, Evans will continue as the company's CFO until a replacement can be found. Myriad will engage a leading executive search firm to conduct a national search and will consider both internal and external candidates for the position.
Myriad Genetics presents myRisk Hereditary Cancer data at ASCO Myriad Genetics announced it will highlight several new clinical studies on its myRisk Hereditary Cancer molecular diagnostic test at the 2015 American Society of Clinical Oncology annual meeting. The myRisk Hereditary Cancer test assesses 25 genes for mutations associated with eight hereditary cancers. Finding deleterious mutations in these genes can help patients with cancer receive appropriate medical care and reduce the risk of second cancers, while patients without cancer can take steps in consultation with their healthcare provider to lower their risk of developing cancer.